From October 1, 2023 to December 31, 2023, the company has repurchased 5,452,563 shares, representing 4.13% for $250 million. With this, the company has completed the repurchase of 17,998,609 shares, representing 13.25% for $750.03 million under the buyback announced on December 9, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.29% | -0.18% | +4.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.36% | 4.9B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.